News

• REIG JOFRE strengthens its leadership in betalactam antibiotic manufacturing with the appointment of Teresa Pérez de Prada as Director of its strategic plant in Toledo
• This appointment reinforces the company’s commitment to innovation, talent, and the universalization of essential health solutions on a global scale

REIG JOFRE, (BME:RJF), a pharmaceutical company listed on the Spanish Stock Exchange, today announced the appointment of Teresa Pérez de Prada as the new Director of its Toledo plant. This appointment consolidates the company’s position as a leader in high-quality antibiotic manufacturing, particularly in the field of betalactam antibiotics, and underscores its mission to universalize global access to essential health solutions.

With over 17 years of experience in the pharmaceutical industry, Teresa Pérez de Prada brings an exceptional academic and professional background. She holds a Ph.D. in Biological Sciences and a Master’s in Immunology from the Complutense University of Madrid. In addition, she has led key Operations and Production areas at international companies such as Takeda and Lonza Biologics. This appointment brings a unique combination of leadership, technical expertise, and a strong commitment to innovation.

The Toledo plant plays a critical role in Reig Jofre’s global strategy. As one of the leading production centers for betalactam antibiotics in Europe, this facility combines operational excellence, advanced technology, and a firm commitment to sustainability. In a rapidly transforming healthcare landscape, REIG JOFRE continues to prioritize talent and collaboration as essential pillars to ensure the sustainability of healthcare systems and drive global innovation.

With the arrival of Teresa Pérez de Prada, REIG JOFRE reaffirms its vision of building a collaborative ecosystem that integrates talent, technology, and purpose, strengthening its position as a leader in essential pharmaceutical solutions for global well-being.